Open Access Repository

New insights and long-term safety of tocilizumab in rheumatoid arthritis

Jones, G ORCID: 0000-0002-9814-0006 and Panova, E 2018 , 'New insights and long-term safety of tocilizumab in rheumatoid arthritis' , Therapeutic Advances in Musculoskeletal Disease, vol. 10, no. 10 , pp. 195-199 , doi: 10.1177/1759720X18798462.

Full text not available from this repository.


Rheumatoid arthritis is a leading musculoskeletal cause of disability in Western society. Therapeutic options have expanded rapidly with the advent of biological agents as treatment options. One of these, tocilizumab, targets the interleukin-6 receptor and has been approved since the late 2000s in many jurisdictions. This approval was based on 6-12 month trials. It is now appropriate to look at longer-term studies and what new insights they have provided into this agent. Data are based largely on observational studies with their well-known limitations as well as some further randomized trials and provide a number of important observations regarding both efficacy and safety. In conclusion, the longer-term data suggest tocilizumab efficacy increases over time for both signs and symptoms and radiographic change. It is also corticosteroid sparing. The safety data are consistent with the shorter-term trials and are largely reassuring but some questions still remain over cardiovascular safety and cancer risk.

Item Type: Article
Authors/Creators:Jones, G and Panova, E
Keywords: cohort, database, long term, rheumatoid, tocilizumab, trials
Journal or Publication Title: Therapeutic Advances in Musculoskeletal Disease
Publisher: Sage Publications Ltd.
ISSN: 1759-720X
DOI / ID Number: 10.1177/1759720X18798462
Copyright Information:

Copyright 2018 The Authors

Related URLs:
Item Statistics: View statistics for this item

Actions (login required)

Item Control Page Item Control Page